Ronald de Wit

Ronald de Wit is a Researcher in the Department of Medical Oncology at Erasmus University Rotterdam with over 300 research outputs spanning prostate cancer, urothelial cancer, and related oncological fields.

His primary research focuses include:

• Castration Resistant Prostate Cancer
• Prostate Cancer treatments (Docetaxel, Cabazitaxel, Enzalutamide)
• Immunotherapy applications (Pembrolizumab)
• Biomarker development for treatment decision-making
• Pharmacological response monitoring

Dr. de Wit's recent publications demonstrate expertise in molecular biomarkers for metastatic urothelial cancer, cell-free DNA analysis in prostate cancer, and risk prediction models for treatment complications. His work bridges translational research with clinical applications, particularly in identifying early response markers and optimizing cancer therapies.

His scientific contributions include:

• Development of novel biomarkers for treatment decision-making
• Analysis of cell-free DNA as early response markers
• Post-hoc analyses of immunotherapy efficacy
• Prediction models for chemotherapy-induced complications

Dr. de Wit has supervised 14 students and presented on cancer pain management and patient education, reflecting his commitment to both research and clinical care aspects of oncology.